|
Eagle Pharmaceuticals inc (NASDAQ: EGRX) |
|
Eagle Pharmaceuticals inc
EGRX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Eagle Pharmaceuticals Inc 's sales fell
by -12.8 % in II. Quarter 2023 from the same quarter a year ago.
Ranking at No. 3126
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -8.1 %
Eagle Pharmaceuticals Inc realized net income compared to net loss a year ago in II. Quarter 2023
• More on EGRX's Growth
|
|
Eagle Pharmaceuticals Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Eagle Pharmaceuticals Inc realized cash reduction of $ -1.61 per share in trailing twelve-month period. |
Company |
0.89 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.04.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.44.
• More on EGRX's Valuation
|
|
|
|
|
Eagle Pharmaceuticals Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Eagle Pharmaceuticals Inc realized cash outflow of $ -1.61per share in trailing twelve-month period. |
Company |
0.89 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.04.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.44.
Eagle Pharmaceuticals Inc Price to Book Ratio is at 0.04 lower than Industry Avg. of 84.23. and higher than S&P 500 Avg. of 0.01
• More on EGRX's Valuation
|
|
EGRX's Profitability Comparisons
|
Eagle Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in II. Quarter 2023 to 15.94 % from 17.76 % in I. Quarter.
Eagle Pharmaceuticals Inc net profit margin of 7.99 % is currently ranking no. 48 in Major Pharmaceutical Preparations industry, ranking no. 120 in Healthcare sector and number 1595 in S&P 500.
|
|
Eagle Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in II. Quarter 2023 to 15.94 % from 17.76 % in I. Quarter.
Eagle Pharmaceuticals Inc net profit margin of 7.99 % is currently ranking no. 48 in Major Pharmaceutical Preparations industry, ranking no. 120 in Healthcare sector and number 1595 in S&P 500.
• More on EGRX's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com